ORLANDO — In this video from the American Academy of Ophthalmology meeting, Michael W. Stewart, MD, discussed results from the phase 2 DAVIO 2 trial on Duravyu in neovascular age-related macular degeneration.
Stewart, professor and chairman of ophthalmology at the Mayo Clinic, said that researchers found that patients who received Duravyu (vorolanib intravitreal insert, EyePoint Pharmaceuticals) “had very good, stable visual acuity over the course of 2 years as well as stable retinal morphology, which was noninferior to the aflibercept 2 mg control group.”
He added that the results “highlight